WO1994005782A1 - Procede de production in vivo d'un organe transgenique par introduction du transgene dans une lumiere - Google Patents
Procede de production in vivo d'un organe transgenique par introduction du transgene dans une lumiere Download PDFInfo
- Publication number
- WO1994005782A1 WO1994005782A1 PCT/US1993/008618 US9308618W WO9405782A1 WO 1994005782 A1 WO1994005782 A1 WO 1994005782A1 US 9308618 W US9308618 W US 9308618W WO 9405782 A1 WO9405782 A1 WO 9405782A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gland
- lumen
- transgene
- dna
- animal
- Prior art date
Links
- 230000009261 transgenic effect Effects 0.000 title claims abstract description 37
- 108700019146 Transgenes Proteins 0.000 title claims abstract description 35
- 210000000056 organ Anatomy 0.000 title claims abstract description 29
- 238000004519 manufacturing process Methods 0.000 title description 8
- 238000001727 in vivo Methods 0.000 title description 4
- 241001465754 Metazoa Species 0.000 claims abstract description 62
- 210000004907 gland Anatomy 0.000 claims abstract description 50
- 210000004027 cell Anatomy 0.000 claims abstract description 43
- 238000000034 method Methods 0.000 claims abstract description 33
- 210000002919 epithelial cell Anatomy 0.000 claims abstract description 30
- 230000028327 secretion Effects 0.000 claims abstract description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 57
- 239000013598 vector Substances 0.000 claims description 32
- 210000005075 mammary gland Anatomy 0.000 claims description 28
- 241000283707 Capra Species 0.000 claims description 12
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 10
- 210000004602 germ cell Anatomy 0.000 claims description 8
- 210000001082 somatic cell Anatomy 0.000 claims description 7
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 claims description 6
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 claims description 6
- 102000006771 Gonadotropins Human genes 0.000 claims description 6
- 108010086677 Gonadotropins Proteins 0.000 claims description 6
- 108091092195 Intron Proteins 0.000 claims description 6
- 241000699670 Mus sp. Species 0.000 claims description 6
- 210000000981 epithelium Anatomy 0.000 claims description 6
- 239000002622 gonadotropin Substances 0.000 claims description 6
- 210000004379 membrane Anatomy 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 6
- 102000018997 Growth Hormone Human genes 0.000 claims description 5
- 108010051696 Growth Hormone Proteins 0.000 claims description 5
- 102000004877 Insulin Human genes 0.000 claims description 5
- 108090001061 Insulin Proteins 0.000 claims description 5
- 108090000445 Parathyroid hormone Proteins 0.000 claims description 5
- 239000003623 enhancer Substances 0.000 claims description 5
- 229940125396 insulin Drugs 0.000 claims description 5
- 210000001325 yolk sac Anatomy 0.000 claims description 5
- 101800000414 Corticotropin Proteins 0.000 claims description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 4
- 241000282898 Sus scrofa Species 0.000 claims description 4
- 239000012190 activator Substances 0.000 claims description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 4
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 3
- 102000011022 Chorionic Gonadotropin Human genes 0.000 claims description 3
- 108010062540 Chorionic Gonadotropin Proteins 0.000 claims description 3
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 claims description 3
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 claims description 3
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 claims description 3
- 102000003951 Erythropoietin Human genes 0.000 claims description 3
- 108090000394 Erythropoietin Proteins 0.000 claims description 3
- 108060003199 Glucagon Proteins 0.000 claims description 3
- 102000009165 Gonadoliberin Human genes 0.000 claims description 3
- 108050000048 Gonadoliberin Proteins 0.000 claims description 3
- 102000009151 Luteinizing Hormone Human genes 0.000 claims description 3
- 108010073521 Luteinizing Hormone Proteins 0.000 claims description 3
- 102000003982 Parathyroid hormone Human genes 0.000 claims description 3
- 102000003946 Prolactin Human genes 0.000 claims description 3
- 108010057464 Prolactin Proteins 0.000 claims description 3
- 102000011923 Thyrotropin Human genes 0.000 claims description 3
- 108010061174 Thyrotropin Proteins 0.000 claims description 3
- 108010042362 beta-Lipotropin Proteins 0.000 claims description 3
- 239000003114 blood coagulation factor Substances 0.000 claims description 3
- 229940015047 chorionic gonadotropin Drugs 0.000 claims description 3
- KLVRDXBAMSPYKH-RKYZNNDCSA-N corticotropin-releasing hormone (human) Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)C(C)C)C(C)C)C1=CNC=N1 KLVRDXBAMSPYKH-RKYZNNDCSA-N 0.000 claims description 3
- 210000004696 endometrium Anatomy 0.000 claims description 3
- 229940105423 erythropoietin Drugs 0.000 claims description 3
- 229960005309 estradiol Drugs 0.000 claims description 3
- 229930182833 estradiol Natural products 0.000 claims description 3
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims description 3
- 229960004666 glucagon Drugs 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 210000000496 pancreas Anatomy 0.000 claims description 3
- 239000000199 parathyroid hormone Substances 0.000 claims description 3
- 230000001817 pituitary effect Effects 0.000 claims description 3
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 3
- 229940097325 prolactin Drugs 0.000 claims description 3
- 210000002307 prostate Anatomy 0.000 claims description 3
- 229960000874 thyrotropin Drugs 0.000 claims description 3
- 230000001748 thyrotropin Effects 0.000 claims description 3
- 210000001519 tissue Anatomy 0.000 claims description 3
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 claims description 2
- 241000283690 Bos taurus Species 0.000 claims description 2
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 claims description 2
- 241000402754 Erythranthe moschata Species 0.000 claims description 2
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 claims description 2
- 210000002533 bulbourethral gland Anatomy 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 claims description 2
- 229960003399 estrone Drugs 0.000 claims description 2
- 229960000890 hydrocortisone Drugs 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 230000001114 myogenic effect Effects 0.000 claims description 2
- 210000002850 nasal mucosa Anatomy 0.000 claims description 2
- 210000002741 palatine tonsil Anatomy 0.000 claims description 2
- 239000000186 progesterone Substances 0.000 claims description 2
- 229960003387 progesterone Drugs 0.000 claims description 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- 102000051325 Glucagon Human genes 0.000 claims 2
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 claims 2
- 102000013566 Plasminogen Human genes 0.000 claims 2
- 108010051456 Plasminogen Proteins 0.000 claims 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims 2
- 229960000258 corticotropin Drugs 0.000 claims 2
- SFVVQRJOGUKCEG-OPQSFPLASA-N β-MSH Chemical compound C1C[C@@H](O)[C@H]2C(COC(=O)[C@@](O)([C@@H](C)O)C(C)C)=CCN21 SFVVQRJOGUKCEG-OPQSFPLASA-N 0.000 claims 2
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 claims 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 claims 1
- 102400000739 Corticotropin Human genes 0.000 claims 1
- 241000283086 Equidae Species 0.000 claims 1
- 229960002478 aldosterone Drugs 0.000 claims 1
- 210000002751 lymph Anatomy 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 108020004414 DNA Proteins 0.000 description 93
- 239000000047 product Substances 0.000 description 43
- 239000000499 gel Substances 0.000 description 26
- 239000002299 complementary DNA Substances 0.000 description 23
- 102000004169 proteins and genes Human genes 0.000 description 23
- 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 description 20
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 description 20
- 235000013336 milk Nutrition 0.000 description 20
- 239000008267 milk Substances 0.000 description 20
- 210000004080 milk Anatomy 0.000 description 20
- 239000000243 solution Substances 0.000 description 18
- 235000018102 proteins Nutrition 0.000 description 17
- 230000001105 regulatory effect Effects 0.000 description 14
- 108091026890 Coding region Proteins 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000008188 pellet Substances 0.000 description 10
- 230000035755 proliferation Effects 0.000 description 10
- 238000001476 gene delivery Methods 0.000 description 9
- 239000012634 fragment Substances 0.000 description 8
- 230000009466 transformation Effects 0.000 description 8
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 6
- 108010076119 Caseins Proteins 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000012083 RIPA buffer Substances 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 230000006651 lactation Effects 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 230000035935 pregnancy Effects 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000011534 wash buffer Substances 0.000 description 6
- 108091061960 Naked DNA Proteins 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 210000004291 uterus Anatomy 0.000 description 5
- 108700024394 Exon Proteins 0.000 description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- ZKHQWZAMYRWXGA-KNYAHOBESA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] dihydroxyphosphoryl hydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)O[32P](O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KNYAHOBESA-N 0.000 description 4
- 229960003589 arginine hydrochloride Drugs 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 239000000122 growth hormone Substances 0.000 description 4
- 238000001114 immunoprecipitation Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 229920001542 oligosaccharide Polymers 0.000 description 4
- 150000002482 oligosaccharides Chemical class 0.000 description 4
- 238000012510 peptide mapping method Methods 0.000 description 4
- 235000020183 skimmed milk Nutrition 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
- 102000011632 Caseins Human genes 0.000 description 3
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 3
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- 102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 3
- 108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000005862 Whey Substances 0.000 description 3
- 102000007544 Whey Proteins Human genes 0.000 description 3
- 108010046377 Whey Proteins Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 229960001230 asparagine Drugs 0.000 description 3
- 235000009582 asparagine Nutrition 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 210000000287 oocyte Anatomy 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 2
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 2
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 2
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 102000001938 Plasminogen Activators Human genes 0.000 description 2
- 108010001014 Plasminogen Activators Proteins 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000003916 acid precipitation Methods 0.000 description 2
- 230000003024 amidolytic effect Effects 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 2
- 239000001099 ammonium carbonate Substances 0.000 description 2
- 238000005571 anion exchange chromatography Methods 0.000 description 2
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 2
- 238000012742 biochemical analysis Methods 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 238000012511 carbohydrate analysis Methods 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000011536 extraction buffer Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 239000012133 immunoprecipitate Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000010189 intracellular transport Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000002879 macerating effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 235000021243 milk fat Nutrition 0.000 description 2
- 108010071421 milk fat globule Proteins 0.000 description 2
- 210000003101 oviduct Anatomy 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 238000000751 protein extraction Methods 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000010474 transient expression Effects 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 241000212384 Bifora Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 238000011537 Coomassie blue staining Methods 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000701533 Escherichia virus T4 Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 101000907783 Homo sapiens Cystic fibrosis transmembrane conductance regulator Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 208000025814 Inflammatory myopathy with abundant macrophages Diseases 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010090665 Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase Proteins 0.000 description 1
- 108091027974 Mature messenger RNA Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 102400000050 Oxytocin Human genes 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 241000609499 Palicourea Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 101000895926 Streptomyces plicatus Endo-beta-N-acetylglucosaminidase H Proteins 0.000 description 1
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 108010090932 Vitellogenins Proteins 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 208000037919 acquired disease Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000010310 bacterial transformation Effects 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- 229940021722 caseins Drugs 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000001378 electrochemiluminescence detection Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 102000056427 human CFTR Human genes 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000004561 lacrimal apparatus Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- -1 polypropylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 210000002254 renal artery Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 210000001625 seminal vesicle Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 201000010653 vesiculitis Diseases 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000006614 vitellogenesis Effects 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 229940045860 white wax Drugs 0.000 description 1
- 235000021247 β-casein Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4712—Cystic fibrosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21069—Protein C activated (3.4.21.69)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- This invention relates to a method for making an organ or gland having a transgene, and nonhu an transgenic animals made in accordance with the present invention.
- DNA molecules have been introduced into cultured cells by calcium phosphate precipitation or electroporation, wherein the DNA enters the cell cytoplasm, with a fraction of the molecules entering the nucleus.
- Graham and Van der Ebb Virology 52:456-467 (1973); Perucho et al, Cell 22:9-17 (1980); Chu et al Nucleic Acids Research 15:1311-1326 (1987); E.J. Robertson, "Teratocarcinomas and Embryonic Stem Cells, A Practical Approach,” (IRL Press 1987); and Bishop & Smith, Molecular Biology Medicine 6:283-298 (1989).
- DNA molecules have also been introduced into the nucleus of cells in culture by direct microinjection.
- Gordon et al Proceedings of the National Academy of Science, USA 77:7380-7384 (1980); Gordon and Ruttel, Methods In Enzymology 101:411-433 (1983); and Wagner and Hoppe, U.S. Patent No. 4,873,191 (1989).
- DNA molecules have been incorporated into animal genomes by a retroviral vector infection. Jaenisch et al, Cell 24:519 (1981); Soriano et al, Science 234:1409-1413 (1986); Stewart et al, Embo. J. 6:383-388 (1987).
- the term “gene transfer” refers to the introduction of new genetic material, either RNA or DNA into the cell.
- the term “germ cells” refers to cells with genetic material that can be passed on to offspring.
- “somatic cells” refer to body cells from which genetic material is not normally passed to offspring.
- “Somatic gene transfer” refers to the introduction of genes not normally present, into somatic cells to provide gene functions that are not normally present in such cell.
- Somatic gene therapy refers to the introduction of normal genes into somatic cells to provide gene functions that are deficient because of genetic or acquired disease.
- Recombinant DNA refers to DNA fragments that have been joined by artificial means through genetic manipulation.
- transformation refers to changes in the property of cells by the introduction of genetic material.
- “Viral mediated gene transfer” refers the introduction of new genetic material into cells by infection with recombinant viruses or fragments of the viral genome containing foreign genes.
- Transcription is a process by which DNA is copied into messenger RNA.
- Translation is a process by which messenger RNA is processed into proteins.
- a regulatory region is a region through which transcription of a gene is controlled or regulated. Such regulatory regions include a cis-acting DNA sequence. A function of this sequence is to be recognized by regulatory elements such as proteins.
- a regulatory region may include promoters, enhancers, and repressors.
- a promoter is a DNA sequence which signals the start of RNA synthesis.
- An enhancer is a DNA sequence that alters the efficiency of transcription.
- a repres ⁇ or is a DNA sequence that reduces the efficiency of transcription.
- the regulatory region can direct the cell or cell type in which the adjacent promoter can function.
- the regulatory region may be derived from a regulatory region that is normally endogenous to the cell which will receive the transgene, or from a regulatory region that is exogenous to the target cell. "Endogenous” is used to denote material which is normally found in the cell to which it refers. The term “exogenous” is used to denote material that is not normally found in the cell to which it refers.
- coding region is a sequence of DNA that encodes for a product and that is free of a regulatory region.
- the coding region can code for any RNA or polypeptide product.
- the product may be a full length gene product or it may be a subfragment thereof, or it may be part of a fusion product.
- a coding region can be sequences which include exon ⁇ and introns, as well as those which include exons and some introns, or only exons.
- the coding region may be derived from a coding region that is normally endogenous to the target cell, or from a coding region that is exogenous to the target cell.
- the coding region may include altered sequences to impart desired features to the encoded protein.
- intron refers to intervening sequence within a gene for the gene product which do not constitute protein coding sequences. In eukaryotic cells, introns are removed from the primary RNA transcript to produce the mature messenger RNA.
- a stop signal is a sequence recognized by a cell to stop transcription.
- a well known stop signal is a polyadenylation signal.
- transgenic product refers to the cellular products produced in response to the presence of a transgene.
- characteristic genotype refers to the complement of genes carried by the somatic cells of the animal, including, without limitation, animals which may have one or more mutations or additional genes in the complement of genes carried by the somatic cells.
- Gland is used in the sense of an organized aggregation of cells functioning as a secretory or excretory organ.
- epidermal cells refers to glandular types cells capable of secretion or excretion.
- lumen refers to the space in the interior of a tubular or cavity type structure.
- One method involves the introduction of recombinant genes into primary cultures of bone marrow, skin, fibroblasts, or hepatic, pancreatic cells then transplanting the transformed cells into live animals.
- small clusters of nonproliferating cells may be transplanted to provide a reservoir of cells producing the recombinant gene product or performing the deficient function normally performed by cells of its type.
- Chronic expression of transgenic products may have profound effects on the animal carrying the gene.
- Superphysiological levels of pharmacologically active molecules may have a detrimental effect on the animal.
- chronic expression of homologous and heterologou ⁇ growth hormone has profound effects on the fat content of domestic species.
- a short term expression system is desired to effectively alter the fat distribution within the animal without causing adverse physiological conditions.
- Such a short term expression system may be considered nontoxic to the food chain.
- a delivery system that can provide transient expression of the transgenic product from 30 to 40 days would have great utility.
- a delivery system that can transform a selected tissue, gland or organ capable of making a transgenic product would have utility particularly where the gland or organ can secrete the transgenic product.
- the gross phenotypic changes associated with other types of transformation systems are avoided.
- the organ can be removed to eliminate foreign DNA from the food chain, and to terminate the production of the transgenic product.
- Embodiments of a present invention feature as an article of manufacture, a nonhuman animal, which animal has a characteristic genotype and has at least one organ or gland which has a lumen having cells which cells are capable of introducing secretions into the lumen or, such cells are, or are capable of forming, germ cells.
- the animal has at least one or more such cells having a transgene which transgene is absent from the characteristic genotype of nonepithelial somatic cells of the nonhuman animal.
- the animal or its progeny is capable of expressing the transgene to make a transgenic product.
- the organ or gland may be selected from the group of glands and organs, comprising by way of example, without limitation, the elementary epithelium, Cowper' s gland, intestinal wall, liver, mammary, nasal mucosa, pancreas, prostate, salivary, sebaceous, seminal vesicles, stomach epithelium, sweat, lacrimal, uterine endometrium, and tonsils.
- glands and organs comprising by way of example, without limitation, the elementary epithelium, Cowper' s gland, intestinal wall, liver, mammary, nasal mucosa, pancreas, prostate, salivary, sebaceous, seminal vesicles, stomach epithelium, sweat, lacrimal, uterine endometrium, and tonsils.
- glands which may have application in the present invention include the musk gland, oil gland, and egg producing glands.
- the organ or gland is the mammary gland.
- the mammary gland provides an efficient production system for pharmaceutical drugs.
- the transfected epithelial cells of the mammary gland can be induced to secrete the transgenic product during the lactation period of the animal .
- the transgene encodes for a gene selected from the group of genes encoding for biologically active molecules.
- biologically active molecules refer to molecules capable of causing some effect within an animal, not necessarily within the animal having the transgene. Such molecules include, by way of example, without limitation, molecules identified in Table I below.
- the tran ⁇ gene compri ⁇ es a coding ⁇ equence for the biologically active molecule, a promoter, and a ⁇ top signal.
- the transgene may also encode for introns to facilitate the handling of the transgene by the molecular machinery of the transformed cell, and enhancers and repre ⁇ or ⁇ to regulate the formation of the tran ⁇ gene product.
- the promoter may exhibit ti ⁇ ue ⁇ pecificity.
- the beta casein promoter, the mou ⁇ e mammary tumor virus promoter, beta lactoglobulin promoter, and whey acid protein promoters are tissue specific for the mammary gland.
- the transgene is carried in a vector which is well received by the epithelial cells lining the lumen and does not have long term effects.
- the Myogenic Vector System (Vector Therapeutics Inc., Hou ⁇ ton, Texas) may provide transient expres ⁇ ion of the tran ⁇ gene in transformed epithelial cells.
- a further embodiment of the present invention features a method of imparting a desired trait to an animal having a characteristic genotype.
- the animal has at least one gland which gland has a lumen lined with epithelial cells, and the epithelial cells are capable of introducing secretions into the lumen.
- the method comprises the step of introducing a transgene into said lumen in vivo.
- the transgene is absorbed into one or more epithelial cells capable of expressing the transgene to make a transgenic product.
- the transgene is expressed when desired, by imposing expressing conditions.
- Expressing conditions will be determined by the choice of promoter, enhancer and repre ⁇ or.
- Expressing conditions may include, by way of example, lactation and exogenous switches such as particular food additive ⁇ .
- the tran ⁇ genic product is ⁇ ecreted by the epithelial cells into the lumen.
- the transgenic product is preferably voided by the lumen where it is capable of being collected, and separated from the other constituents of the lumen secretions.
- Preferred animals for the pre ⁇ ent method include rodent ⁇ , ⁇ uch as lagamorphs, mice and rat ⁇ and domestic animals, such as cow, swine, goat and other milk producing domestic animals.
- Organ ⁇ and glands can be transformed to replace the normal functions of a disea ⁇ ed organ.
- a pancrea ⁇ incapable of producing insulin could receive a transgene for insulin.
- a gland other than the organ or gland which would normally make a biologically active molecule, may be transformed to supply is ⁇ ing product.
- Table I lists examples of pharmacologically active molecules capable of being made by transformed epithelial cells.
- Figure 1 shows the structure of a mammary specific expression vector.
- the 17.8 kilobase icroinjected fragment contains the entire human CFTR cDNA cloned between exons 2 and 7 of the goat beta casein gene.
- the solid line depicts the goat beta casein gene and the block identified with angled hatch marks represents the CFTR cDNA.
- Figure 2 ⁇ how ⁇ the structure of the WAP-LAtPA expression vector and its restriction enzyme sites.
- H represents Hind III
- R represent ⁇ EcoRI
- X represent ⁇ Xbal
- B represents BamHI
- K represents Kpml .
- the present invention is described in detail as a method for transforming epithelial cells of a gland or organ of animals which animals are then capable of producing a transgenic product.
- the present Example present ⁇ an overview of the process applied to selected DNA, animals and glands.
- the DNA may be cDNA or genomic.
- cDNA clones may be obtained from the American Type Culture Collection, universities, and corporate and private research groups.
- the coding sequence can be obtained from natural sources in a manner known in the art. The manner of isolating such genes is not necessarily simple; however, the methodology of the present invention applies equally to such coding sequences which have been identified as relating to a particular product as well as coding sequences which are likely to be discovered in the future.
- the DNA, whether cDNA or genomic DNA may be modified by molecular cloning techniques.
- the coding sequences for the transgenic product is coupled with appropriate regulatory regions.
- the choice of regulatory region and signal peptide will be influenced by the animal and gland to be transformed.
- promoters specific for the mammary gland have been isolated which function to cause secretory epithelial cells to release transgenic products in milk.
- promoters appear to function in species from which such promoter ⁇ were i ⁇ olated and others.
- a DNA vector i ⁇ prepared by ⁇ olubilizing the naked DNA comprising the coding sequence and regulatory region into a solution of Tris-HCl (pH 7.4) and EDTA.
- the DNA vector may co pri ⁇ e a pellet of precipitated DNA.
- DNA can be precipitated from solutions with ethanol.
- the pellet may be encapsulated to provide slow release of the DNA.
- the DNA vector may also have features of a gel . DNA imparts viscosity to solutions in which it is dis ⁇ olved. By adju ⁇ ting the concentrations of solutions containing DNA, the DNA solution may assume gel-like features.
- the DNA may have features of a gel due to the addition of excipients ⁇ uch a ⁇ methyl cellulo ⁇ e, ⁇ odium alginate and the like.
- the gel-like feature ⁇ may provide a ⁇ low relea ⁇ e of the DNA into epithelial cell ⁇ of gland ⁇ .
- the gel may al ⁇ o take the form of oleaginou ⁇ gel having a ba ⁇ e of white petrolatum, oleic acid white wax or paraffin and admixture ⁇ and variou ⁇ combination ⁇ of ⁇ uch ba ⁇ e.
- DNA may be ab ⁇ orbed or encap ⁇ ulated in lipid ve ⁇ icles or liposome ⁇ .
- the lipid ve ⁇ icles may also comprise binding agents to convey specificity to particular epithelial cells of the gland. For example, coupling the lipid ve ⁇ icle ⁇ to vitellogenin or very low density lipoprotein may convey specificity for chicken oocytes. Barber et al, "The Receptor for Yolk Lipoprotein Depo ⁇ ition in the Chicken Oocyte," J. Biol. Chem. , Vol 266, No. 28:18 761-18770 (1991).
- DNA vector will be influenced by the feature ⁇ of the gland in which the epithelial cell ⁇ are to be tran ⁇ formed.
- the oocyte of bird ⁇ may be tran ⁇ formed with a DNA vector encap ⁇ ulated in lipid ve ⁇ icles.
- the lipid vesicles are injected into the maternal arterial supply during vitellogenesis.
- Transformation of an embryo in utero or germ cells may be performed by direct injection into the embryonic yolk sac in the region where the primordial germ cells will migrate to the genital ridge.
- a preferred DNA vector system is comprised of DNA in solution.
- the mammary of gland of mammals may be transformed by injection of DNA ⁇ olution ⁇ through ⁇ terile teat infu ⁇ ion cannula ⁇ that fit Luer-lock syringes.
- Suitable DNA vectors for the transformation of the mammary gland compri ⁇ e naked DNA in solution, naked DNA in a pelleted form, or naked DNA in a viscous gel.
- urethra of animals may be transformed with the aid of a rubber urethral catheter or Foley catheter.
- Suitable vehicles for gene delivery comprise DNA in solution, DNA in a slow relea ⁇ e pelleted form, and DNA in a viscous gel.
- the vagina may be transformed with the aid of a vaginal ⁇ peculum with light, in ⁇ emination pipette ⁇ / ⁇ emen ⁇ traws, french style straw guns with sheaths, and uterine catheters.
- Suitable vehicles for gene delivery comprise DNA in solution, DNA in a slow release pelleted form and DNA in a viscou ⁇ gel.
- the oviduct may be transformed with the aid of standard surgical approach requiring a surgical pack, glass pipette and metal pipettor; or, in the alternative, a laparoscopic approach requiring a ⁇ traight endoscope, laparo ⁇ copy holding forcep ⁇ , ⁇ tainless steel trocar and cannula, (7 mm X 7 cm), paravertebral needle, and a siliconized gla ⁇ pipette attached to a ⁇ yringe.
- Suitable DNA vectors for each approach comprise DNA in solution, DNA in a slow release pelleted form, and DNA in a viscou ⁇ gel.
- Epithelial cells of the uterus may be tran ⁇ formed in at least three ways. Fir ⁇ t, epithelial cell ⁇ of the uterus can be transformed with surgical laparoscopic approaches a ⁇ set forth with respect to the oviduct. In the alternative, epithelial cells of the uterus may be transformed with uterine pipette ⁇ with drilled ends for attachment to a syringe. A third alternative to transform epithelial cells of the uterus comprise ⁇ a uterine catheter. In each of the alternatives, the vehicle for gene delivery may comprise a DNA in solution, DNA in a slow relea ⁇ e pelleted form, or DNA in a viscous gel.
- Epithelial cells of the ovary may be transformed with standard surgical procedures involving direct injection of the DNA vector into the ovarian artery using needle and syringe.
- Suitable gene delivery vehicles comprise DNA in ⁇ olution, DNA in ⁇ low release pelleted form, and DNA in encapsulated lipid vesicles.
- the kidney can be transformed with the aid of standard surgical approache ⁇ with the direct injection into the ureter or renal artery; or, ureteral catheterization following cystostomy.
- a second alternative comprises ureteral catheterization using cy ⁇ to ⁇ copy. Such technique ⁇ require an endo ⁇ cope, catheter, trocar and holding forcep ⁇ .
- a third alternative is percutaneous nephropyelocentesi ⁇ using fluoro ⁇ copy equipment.
- Vehicles for DNA gene delivery comprise DNA in ⁇ olution, DNA in ⁇ low release pelleted form ⁇ , and DNA in a viscous gel.
- the colon/rectum may be transformed with the aid of a Bordex or Foley catheter of the type used to fill and hold fluid in place for barium enemas.
- Suitable vehicles for gene delivery comprise DNA in solution, DNA in slow release pelleted form ⁇ , and DNA in vi ⁇ cou ⁇ gel.
- the pro ⁇ tate gland may be tran ⁇ formed by direct injection by palpication through the rectum a ⁇ for biop ⁇ y examination ⁇ .
- Suitable vehicles for gene delivery comprise DNA in solution, DNA in pelleted form, and DNA in a viscou ⁇ gel.
- the salivary gland may be tran ⁇ formed with direct injection ⁇ into the duct using a blunt needle and syringe a ⁇ for a ⁇ ialogram.
- Suitable vehicle ⁇ for gene delivery comprise DNA in a ⁇ olution, DNA in pelleted form ⁇ , and DNA in a viscou ⁇ gel.
- the lacrimal gland may be transformed with a prolonged release device such as a permeable membrane-type ocular insert of the type marketed under the trademark Ocusert® (ALSA) .
- a prolonged release device such as a permeable membrane-type ocular insert of the type marketed under the trademark Ocusert® (ALSA) .
- An alternative comprises a DNA contained in an eye ointment/solution with a temporary clo ⁇ ure of the lacrimal duct to prevent drainage.
- the temporary clo ⁇ ure of the lacrimal duct can be performed with nylon thread.
- Suitable vehicle ⁇ for gene delivery compri ⁇ e DNA in ⁇ olution, DNA in a viscous gel, or DNA in a pelleted form.
- the transformation event is performed during a period in which the organ or gland has epithelial cell ⁇ undergoing rapid proliferation.
- epithelial cell ⁇ can take place during the fetal, new born, and infant stages of the animals' life and at other times during the development of the animal.
- the areolar structures of the mammary gland undergo rapid proliferation prior to puberty, during induction with steroid ⁇ and during pregnancy.
- the secretions can be collected and the transgenic product separated from the other constituent ⁇ of the secretions.
- Example 2 outlines the production of cystic fibrosi ⁇ tran ⁇ membrane conductance regulator in the epithelial cell ⁇ of the mammary gland of goat ⁇ .
- Other tran ⁇ genic products can be readily substituted for cystic fibrosis transmembrane conductance regulator and the construction of the tran ⁇ gene and vector ⁇ ystems can be altered as known in the art.
- Partial CFTR cDNA clone ⁇ Til, T16-1, T16-4.5 and C-l/5 are obtainable from the American Type Culture Collection (Rockland, Maryland). Riordan et al, "Identification of the cy ⁇ tic fibrosis gene: cloning and characterization of the complementary DNA, " Science, 245:1059-1065 (1989). The alignment of the CFTR cDNA portion of these clones is pre ⁇ ented in Figure 1. The full length copy of CFTR cDNA (containing a point mutation at re ⁇ idue 936 to activate an internal cryptic bacterial promoter that otherwi ⁇ e renders the cDNA unstable) is in ⁇ erted between exons 2 and 7 of the goat beta ca ⁇ ein gene.
- the DNA vector may take the form of high concentration solution or gel or a pellet to be placed directly into the lumen of the gland.
- the DNA vector is directly introduced by injection via the orifice and duct leading into the lumen of the mammary gland.
- the DNA vector is prepared by solubilizing the naked DNA into a ⁇ olution of Tri ⁇ -HCl (pH 7.4) and EDTA.
- the DNA vector can be introduced into the lumen of the gland in a plurality of tran ⁇ formation event ⁇ .
- the epithelial cell ⁇ take up the DNA vector and are capable of expre ⁇ ing the tran ⁇ gene. Expression is induced with lactation.
- the transgenic product is separated from the remaining constituents of milk and can be further processed if necessary.
- the milk i ⁇ either diluted with an equal volume of phosphate buffer saline or fractionated as described by Imam et al, "Isolation and Characterization of a Major Glycoprotein From Milk Fat Globule Membrane of Human Breast Milk," Biochem. J. , 193:47-54 (1981); and, Patton and Huston, "A Method For I ⁇ olation of Milk Fat Globules," Lipids 21:170-174 (1986).
- Milk is solubilized and further diluted 5 fold in RIPA buffer (50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 1% Triton X-100, 1% ⁇ odium deoxycholate and 0.1% ⁇ odiu ⁇ ulphate) prior to biochemical analy ⁇ i ⁇ .
- RIPA buffer 50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 1% Triton X-100, 1% ⁇ odium deoxycholate and 0.1% ⁇ odiu ⁇ ulphate
- wash buffer 10 mM Tris-HCl, pH 7.5, 0.25 M sucrose and 1 mM MgCl-
- the resulting skim milk is siphoned off by inserting a needle through the layer of cream.
- the cream i ⁇ washed twice with approximately one volume of wash buffer and dispersed in RIPA buffer.
- the siphoned skim milk i ⁇ centrifuged at 12,000g for 10 minute ⁇ to pellet the ca ⁇ ein ⁇ .
- the ca ⁇ ein pellet i ⁇ wa ⁇ hed once with one volume of wash buffer and re ⁇ u ⁇ pended in RIPA buffer.
- Membrane ⁇ and ve ⁇ icle ⁇ contained in the resultant skim supernatant were collected by further centrifugation at 100,000g for 2 hours.
- CFTR-containing immunoprecipitates is achieved by incubating with protein kinase A and [ ⁇ 32P]ATP (10 ⁇ Ci) in a final volume of 50 ⁇ l in kinase buffer (50 mM Tri ⁇ -HCl, pH 7.5, 10 mM MgCl_ and 100 ⁇ g ml bovine serum albumin) at 30°C for 60 minute ⁇ .
- kinase buffer 50 mM Tri ⁇ -HCl, pH 7.5, 10 mM MgCl_ and 100 ⁇ g ml bovine serum albumin
- N-glycanase, endoglycosidase H and endoglycosidase F are obtained from Genzyme Corp. (Cambridge, Mas ⁇ achu ⁇ etts) . Conditions for digestion with the re ⁇ pective glyco ⁇ idases were as specified by the manufacturer, except that incubations are performed at 37°C for 4 hours only.
- CFTR is immunopurified u ⁇ ing the polyclonal antibody pAb Ex 13, phosphorylated in vitro with protein kina ⁇ e A and
- [ ⁇ 32P]ATP ⁇ eparated on SDS-polyacrylamide gel ⁇ , and then extracted from the gel ⁇ by macerating the gel piece ⁇ in protein extraction buffer (50 mM ammonium bicarbonate, 0.1% SDS and 0.2% ⁇ -mercaptoethanol) .
- Eluted protein ⁇ are recovered by trichloroacetic acid precipitation.
- Example 3 outline ⁇ the production of cystic fibrosis transmembrane conductance regulator in the epithelial cell ⁇ of the mammary gland ⁇ of mice.
- Other tran ⁇ genic products can be readily ⁇ ubstituted for the cystic fibrosis transmembrane conductance regulator and the construction of the transgene vector sy ⁇ tem ⁇ can be altered i ⁇ known in the art.
- Partial CFTR cDNA clones Til, T16-1, T16-4.5 and C-l/5 are obtainable from the American Type Culture Collection (Rockland, Maryland). Riordan et al, "Identification of the cystic fibro ⁇ i ⁇ gene: cloning and characterization of the complementary DNA," Science, 245:1059-1065 (1989). The alignment of the CFTR cDNA portion of the ⁇ e clone ⁇ i ⁇ pre ⁇ ented in Figure 1.
- the full length copy of CFTR cDNA (containing a point mutation at re ⁇ idue 936 to activate an internal cryptic bacterial promoter that otherwi ⁇ e render ⁇ the cDNA un ⁇ table) i ⁇ in ⁇ erted between exon ⁇ 2 and 7 of the goat beta casein gene.
- the DNA vector may take the form of high concentration solution or gel or a pellet to be placed directly into the lumen of the gland.
- the high concentration DNA solution will comprise approximately 1 ⁇ g DNA in 10 mM Tri ⁇ -HCl pH 7.6, 1 mM EDTA.
- the molarity of the DNA can be adju ⁇ ted to create a vi ⁇ cou ⁇ gel.
- the DNA may compri ⁇ e a pellet of DNA precipitated with ethanol.
- the DNA vector i ⁇ directly introduced by injection via the orifice and duct leading into the lumen or the mammary gland.
- the DNA vector can be introduced into the lumen of the gland in a plurality of transformation events.
- the epithelial cells take up the DNA vector and are capable of expressing the transgene to produce a transgenic product.
- mice are injected with oxytocin (250 mlU) and milked 5 minutes later with a suction device.
- the milk is either diluted with an equal volume of phosphate buffer saline or fractionated as described by Imam et al., "Isolation and Characterization of a Major Glycoprotein From Milk Fat Globule Membrane of Human Brea ⁇ t Milk," Biochem. J. , 193:47-54 (1981); and, Patton and Hu ⁇ ton, "A Method For I ⁇ olation of Milk Fat Globule ⁇ ," Lipid ⁇ 21:170-174 (1986).
- the casein pellet is washed once with one volume of wash buffer and resu ⁇ pended in RIPA buffer.
- Membranes and vesicle ⁇ contained in the resultant skim supernatant were collected by further centrifugation at 100,000g for 2 hours.
- CFTR-containing immunoprecipitates is achieved by incubating with protein kinase A and [ ⁇ 32P]ATP (10 ⁇ Ci) in a final volume of 50 ⁇ l in kinase buffer (50 mM Tris-HCl, pH 7.5, 10 mM MgCl- and 100 ⁇ g ml ⁇ bovine serum albumin) at 30°C for 60 minute ⁇ .
- kinase buffer 50 mM Tris-HCl, pH 7.5, 10 mM MgCl- and 100 ⁇ g ml ⁇ bovine serum albumin
- N-glycanase endoglyco ⁇ ida ⁇ e H and endoglyco ⁇ ida ⁇ e F are obtained from Genzyme Corp. (Cambridge, Ma ⁇ achu ⁇ ett ⁇ ) .
- Condition ⁇ for dige ⁇ tion with the re ⁇ pective glycosidase ⁇ were a ⁇ specified by the manufacturer, except that incubations are performed at 37°C for 4 hours only.
- [ ⁇ 32P]ATP [ ⁇ 32P]ATP, ⁇ eparated on SDS-polyacrylamide gels, and then extracted from the gels by macerating the gel pieces in protein extraction buffer (50 mM ammonium bicarbonate, 0.1% SDS and 0.2% ⁇ -mercaptoethanol) . Eluted proteins are recovered by trichloroacetic acid precipitation.
- Example 4 features the transformation of the mammary gland of goat ⁇ with a tran ⁇ gene encoding for ti ⁇ ue-type plasminogen activator (TPA) .
- the expression vector WAP-TPA was generated by fusing a 2.6 kilobase EcoRI-Kpnl fragment upstream of the murine whey acid protein gene to a cDNA encoding wild-type human TPA.
- the DNA vector i ⁇ placed as a high concentration solution, or in a pellet form into the lumen of the mammary gland for tran ⁇ fection.
- the DNA is placed in the mammary gland of a goat prior to puberty or during rapid proliferation of the areolar structure ⁇ in the developing mammary gland during pregnancy, during the period of time when the mammary gland undergoes rapid proliferation. Proliferation of mammary gland can occur either during early pregnancy or induced with steroid hormones regimes. Alternatively, the DNA implant can be made during the first pregnancy of the female at a time where maximum proliferation occurs.
- the vector ⁇ y ⁇ tem can be delivered ⁇ everal time ⁇ during the proliferative event to increa ⁇ e the number of tran ⁇ fected ⁇ ecretory cell ⁇ .
- the animal produces TPA during the animal's lactation period.
- the milk of transgenic goats is collected and frozen.
- the transgenic goat' ⁇ milk containing LAtPA is thawed, pooled and the pH adju ⁇ ted to 4.4 using glacial acetic acid.
- the resultant precipitate is removed by centrifugation at 8,000xg for 20 min. at 4°C.
- the ⁇ upernate is adjusted to pH 5.5 with NaOH and filtered through a 0.22 ⁇ polypropylene filter cartridge.
- This whey fraction i ⁇ applied at a flow rate of 100 cm/h to a Butyl-Toyopearl 650C column (2.5 x 6.5 cm) which is equilibrated in 0.02 M sodium phosphate, 0.1 M arginine-HCl, 0.01% tween 80, pH 6.0.
- the column is ⁇ ubsequently wa ⁇ hed with equilibration buffer and the LAtPA eluted with 0.2 M ⁇ odium pho ⁇ phate, 0.1 M arginine-HCl and 70% ethylene glycol.
- Fractions containing LAtPA, as judged by indirect amidolytic assay, are pooled and diluted 1:2 with 100 mM arginine-HCl, pH 6.0 and loaded at 15 cm/h on to an 1 x 15 cm immunoaffinity column constructed with an anti-human tPA monoclonal antibody designated 17-3.
- the column is washed extensively and LAtPA eluted from the column with 0.1 M glycine, 0.4 M arginine-HCl, 0.5 M NaCl, 0.01% tween 80, pH 2.5. Elution of the enzyme from the column i ⁇ monitored by absorbance (280 nm) and LAtPA containing fractions are immediately pooled and the pH adju ⁇ ted to 7.0 with NaOH.
- the ⁇ ample was then filtered through a 0.22 ⁇ Millex-GV filter and applied to a 250 x .4 mm Synchrom Syncropak pentyl HPLC column.
- the column is equilibrated and washed with 20 mM sodium phosphate, 150 mM NaCl, 8 mM epsilon amino-n-caproic acid (EACA) , pH 6.0, developed with a 0-90% propylene glycol gradient and protein elution monitored by absorbance at 280 nm.
- Protein containing fraction ⁇ are analyzed by SDS gel electrophore ⁇ i ⁇ , protein band ⁇ visualized by Coomassie blue staining and fractions pooled to provide a preparation of greater than 98% protein purity.
- Purified LAtPA is ⁇ tored frozen at -80°C.
- the blots are blocked with 5% (w/v) nonfat dry milk to reduce nonspecific binding and the LAtPA band ⁇ were vi ⁇ ualized by a combination of a rabbit anti-human tPA antibody (American Diagnostica, Chicago, IL) , a goat anti-rabbit IgG conjugated to horseradish peroxidase (Cappel Corp., We ⁇ tchester, PA) and the Enhanced Chemiluminescence System (Amersham Corp., Arlington Height ⁇ , IL) .
- a rabbit anti-human tPA antibody American Diagnostica, Chicago, IL
- a goat anti-rabbit IgG conjugated to horseradish peroxidase Cappel Corp., We ⁇ tchester, PA
- the Enhanced Chemiluminescence System Amersham Corp., Arlington Height ⁇ , IL
- Amino acid ⁇ equence analysis is performed using an Applied Bio ⁇ ystem ⁇ 477 ga ⁇ pha ⁇ e ⁇ equencer.
- PTH amino acid analy ⁇ is i ⁇ performed with an on-line Applied Biosystems 2.1 x 220 mm PTH C-18 column.
- Carbohydrate compositional analysi ⁇ is performed according to the method of Hardy et al, "Monosaccharide
- sample protein ⁇ (Dionex, Sunnyvale, CA) .
- 6 to ten nmoles of sample protein ⁇ are hydrolyzed in 2 M trifluoroacetic acid, for 2 h at 121°C.
- Sialic acid content of the protein ⁇ i ⁇ determined by thiobarbituric acid method as modified by Powell and Hart,
- transfection event can be facilitated with the u ⁇ e of retroviru ⁇ e ⁇ and lipo ⁇ ome ⁇ .
- pre ⁇ ent examples feature the use of goats and mice, any domestic animal such as cow ⁇ , swine and other animals ⁇ uch as rabbits, mice, rats and guinea pigs may be used.
- the present invention is amenable to the making of any transgenic product for which cDNA or genomic DNA can be identified.
- the present method ⁇ for tran ⁇ forming ⁇ pecific organ ⁇ or gland ⁇ allow ⁇ the production of the tran ⁇ genic product to be controlled by the ⁇ election of regulatory region ⁇ , and by removal of none ⁇ ential glands or organs producing the tran ⁇ genic product. Thu ⁇ , the pre ⁇ ent delivery ⁇ y ⁇ tem may be used to obtain transient expression of the transgenic product from 30 to 40 days.
- the present invention is also suitable for therapeutic applications where it is desirable to complement an animal ⁇ ' characteristic genotype with a transgene.
- Such application ⁇ are u ⁇ eful where, by virtue of a mutation or other event, the individual lack ⁇ a particular gene; or where, by virtue of di ⁇ ea ⁇ e, the individual cannot make a gene product; for example, diabetic ⁇ cannot make in ⁇ ulin; or where, by virtue of di ⁇ ea ⁇ e, the individual make ⁇ a defective gene product.
- any other gland or organ sy ⁇ tem having a lumen lined with epithelial cells can be transformed in a similar manner.
- the present invention i ⁇ capable variation and modification and, therefore, the present invention ⁇ hould not be limited to the preci ⁇ e detail ⁇ ⁇ et forth, but ⁇ hould include ⁇ uch change ⁇ in alteration ⁇ a ⁇ fall within the purview of the following claim ⁇ .
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Environmental Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Public Health (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
L'invention concerne un animal non humain qui possède au moins un organe ou une glande, ledit organe ou glande présentant une lumière doublée de cellules épithéliales capables d'introduire des sécrétions dans la lumière, au moins une ou plusieurs cellules épithéliales comprenant un transgène absent du génotype caractéristique de l'animal, cette cellule étant capable d'exprimer ledit transgène afin de former un produit transgénique. L'invention porte également sur un procédé permettant de donner un trait désiré à un animal par la lumière et dans les cellules épithéliales, ces dernières étant capables d'exprimer le transgène afin de fabriquer un produit transgénique.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94305992A | 1992-09-10 | 1992-09-10 | |
US07/943,059 | 1992-09-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994005782A1 true WO1994005782A1 (fr) | 1994-03-17 |
Family
ID=25479045
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1993/008618 WO1994005782A1 (fr) | 1992-09-10 | 1993-09-10 | Procede de production in vivo d'un organe transgenique par introduction du transgene dans une lumiere |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO1994005782A1 (fr) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996020013A1 (fr) * | 1994-12-24 | 1996-07-04 | Cambridge University Technical Services Limited | Amelioration de la fonction endometriale ou s'y rapportant |
WO1998015634A1 (fr) * | 1996-10-07 | 1998-04-16 | Wisconsin Alumni Research Foundation | Promoteurs specifiques a la glande mammaire |
US5824543A (en) * | 1995-06-05 | 1998-10-20 | New York University | Method for expression and isolation of biologically active molecules in urine using a mouse uroplakin-II promoter |
US6210736B1 (en) | 1997-06-17 | 2001-04-03 | Genzyme Transgenics Corporation | Transgenically produced prolactin |
KR100582915B1 (ko) * | 1994-12-24 | 2006-08-30 | 캠브리지 유니버시티 테크니칼 서비스 리미티드 | 자궁내막기능또는자궁내막기능과관련된기능의개선방법 |
US8722384B2 (en) | 1997-04-11 | 2014-05-13 | Calgene Llc | Methods and compositions for synthesis of long chain polyunsaturated fatty acids |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1987005325A1 (fr) * | 1986-03-03 | 1987-09-11 | Transgene Gmbh | Procede pour transferer des substances organiques et/ou inorganiques a des cellules-oeufs et/ou a des cellules somatiques d'animaux, et compositions utilisees a cet effet |
WO1991006309A1 (fr) * | 1989-11-03 | 1991-05-16 | Vanderbilt University | Procede d'administration in vivo de genes etrangers fonctionnels |
WO1993012440A1 (fr) * | 1991-12-19 | 1993-06-24 | The Secretary Of State For Defence In Her Britannic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland | Reseau conformateur de faisceau digital |
WO1993012756A2 (fr) * | 1991-12-17 | 1993-07-08 | The Regents Of The University Of California | Transfection pulmonaire par administration transgenique aerosol |
-
1993
- 1993-09-10 WO PCT/US1993/008618 patent/WO1994005782A1/fr active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1987005325A1 (fr) * | 1986-03-03 | 1987-09-11 | Transgene Gmbh | Procede pour transferer des substances organiques et/ou inorganiques a des cellules-oeufs et/ou a des cellules somatiques d'animaux, et compositions utilisees a cet effet |
WO1991006309A1 (fr) * | 1989-11-03 | 1991-05-16 | Vanderbilt University | Procede d'administration in vivo de genes etrangers fonctionnels |
WO1993012756A2 (fr) * | 1991-12-17 | 1993-07-08 | The Regents Of The University Of California | Transfection pulmonaire par administration transgenique aerosol |
WO1993012440A1 (fr) * | 1991-12-19 | 1993-06-24 | The Secretary Of State For Defence In Her Britannic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland | Reseau conformateur de faisceau digital |
Non-Patent Citations (4)
Title |
---|
ROSENFELD, M. A. ET AL.: "Adenovirus-mediated transfer of a recombinant alpha1-antitrypsin gene to the lung epithelium in vivo", SCIENCE, vol. 252, no. 5004, 19 April 1991 (1991-04-19), LANCASTER, PA US, pages 431 - 434 * |
ROSENFELD, M.A. ET AL.: "In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium", CELL., vol. 68, no. 1, 10 January 1992 (1992-01-10), CAMBRIDGE, NA US, pages 143 - 155 * |
STRIBLING, R. ET AL.: "Aerosol gene delivery in vivo", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA., vol. 89, no. 23, 1 December 1992 (1992-12-01), WASHINGTON US, pages 11277 - 11281 * |
YOSHIMURA, K. ET AL.: "Expression of the human cystic fibrosis transmembrane conductance regulator gene in the mouse lung after invivo intratracheal plasmid mediated gene transfer", NUCLEIC ACIDS RESEARCH., vol. 20, no. 12, June 1992 (1992-06-01), ARLINGTON, VIRGINIA US, pages 3233 - 3240 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996020013A1 (fr) * | 1994-12-24 | 1996-07-04 | Cambridge University Technical Services Limited | Amelioration de la fonction endometriale ou s'y rapportant |
AU712278B2 (en) * | 1994-12-24 | 1999-11-04 | Cambridge University Technical Services Limited | Improvements in or relating to endometrial function |
US6472374B1 (en) * | 1994-12-24 | 2002-10-29 | Cambridge University Technical Services Limited | Endometrial function |
KR100582915B1 (ko) * | 1994-12-24 | 2006-08-30 | 캠브리지 유니버시티 테크니칼 서비스 리미티드 | 자궁내막기능또는자궁내막기능과관련된기능의개선방법 |
US5824543A (en) * | 1995-06-05 | 1998-10-20 | New York University | Method for expression and isolation of biologically active molecules in urine using a mouse uroplakin-II promoter |
WO1998015634A1 (fr) * | 1996-10-07 | 1998-04-16 | Wisconsin Alumni Research Foundation | Promoteurs specifiques a la glande mammaire |
US8722384B2 (en) | 1997-04-11 | 2014-05-13 | Calgene Llc | Methods and compositions for synthesis of long chain polyunsaturated fatty acids |
US6210736B1 (en) | 1997-06-17 | 2001-04-03 | Genzyme Transgenics Corporation | Transgenically produced prolactin |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6441145B1 (en) | Transgenically produced Antithrombin III | |
US6344596B1 (en) | Expression of active human factor IX in mammary tissue and of milk non human transgenic mammals | |
US7939317B1 (en) | Transgenic animals secreting desired proteins into milk | |
US4873316A (en) | Isolation of exogenous recombinant proteins from the milk of transgenic mammals | |
DE69232310T2 (de) | Expression von aktivem menschlichem Protein C im Milchdrüsengewebe transgener Tiere | |
US7888321B2 (en) | Production of high levels of transgenic factor IX without gene rescue, and its therapeutic uses | |
US5780009A (en) | Direct gene transfer into the ruminant mammary gland | |
JPH02104284A (ja) | エリトロポエチンを発現するヒトcDNAまたはヒトgDNAのクローニング方法 | |
US6727405B1 (en) | Transgenic animals secreting desired proteins into milk | |
US5814716A (en) | Cell lines from a transgenic mouse which express biologically active IX factor | |
US7435869B2 (en) | Transgenic nonhuman mammals producing fibrinogen in milk and methods of producing fibrin | |
US20130131317A1 (en) | Expression of secreted human alpha-fetoprotein in transgenic animals | |
WO1994005782A1 (fr) | Procede de production in vivo d'un organe transgenique par introduction du transgene dans une lumiere | |
JPH05194264A (ja) | 血栓塞栓障害治療剤 | |
EP1379677A2 (fr) | Production de niveaux eleves du facteur transgenique ix sans sauvetage de genes, et ses utilisations therapeutiques | |
US20030046716A1 (en) | Transgenically produced platelet derived growth factor | |
RU2345088C2 (ru) | Способ получения рекомбинантных белков в молочной железе нетрансгенных млекопитающих | |
US20040117862A1 (en) | Production of high levels of transgenic factor VII with engineered stability and its therapeutic uses | |
Butler | Production and secretion of recombinant human fibrinogen by the transgenic murine mammary gland | |
Velander et al. | TRANSGENIC NONHUMAN MAMMALS PRODUCING FIBRINOGEN IN MILKAND METHODS OF PRODUCING FIBRIN | |
AU2002305043A1 (en) | Production of high levels of trangenic factor IX without gene rescue, and its therapeutic uses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase |